News Feature

Filter By:

  • Despite its checkered reputation, cryptocurrency is being considered by a handful of academics as a means to funnel funds into translational research. Is the trend likely to spread? Laura DeFrancesco and Ariel Klevecz investigate.

    • Laura DeFrancesco
    • Ariel Klevecz
    News Feature
  • After >20 years of research at the intersection of virology and immunology, two brothers have launched a venture seeking to turn arenaviruses into an anticancer virotherapy.

    • Laura DeFrancesco
    News Feature
  • In the ascendant world of mRNA medicines, circular RNA shows promise as an alternative way for making proteins inside human cells.

    • Ken Garber
    News Feature
  • Improving target selectivity and defining cell phenotypes may improve the odds of finding therapies for fibrosis.

    • Melanie Senior
    News Feature
  • After decades of research and development, devices for detecting infectious agents in breath are finally maturing, with SARS-CoV-2 galvanizing progress. Carrie Arnold reports.

    • Carrie Arnold
    News Feature
  • Whole-genome sequencing may be the fastest way to diagnose rare complex diseases, but should it be incorporated into healthy newborn screening?

    • Caroline Seydel
    News Feature
  • Protective encapsulating devices and gene-editing technologies could obviate the need for antirejection drugs in stem-cell-derived therapies for diabetes.

    • Elie Dolgin
    News Feature
  • Investment in small-molecule protein degraders is surging, but their drawbacks, limitations and risks are becoming clear.

    • Ken Garber
    News Feature
  • In China, the first children with germline-edited genomes are growing up. How might their edited genomes affect their lives?

    • Vivien Marx
    News Feature
  • Whether pan-vaccines or antibodies, SARS-CoV-2 is adding impetus to the race for broad-spectrum countermeasures against the world’s next infectious scourges.

    • Laura DeFrancesco
    News Feature
  • Nature Biotechnology’s annual survey highlights university startups that are, among other things, rethinking how to deliver gene-editing therapy and tackling various metabolic conditions, immune disorders and cancer with microbiome treatments or immunotherapy. Michael Eisenstein, Ken Garber, Esther Landhuis, Caroline Seydel and Laura DeFrancesco report.

    • Michael Eisenstein
    • Ken Garber
    • Laura DeFrancesco
    News Feature